Clinical Trials Browser

NCT04071223 2026-03-18

Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study

Phase 2 Active not recruiting

134 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT03344211 2026-02-27

Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer

Phase 2 Active not recruiting

30 enrolled

Genitourinary

Prostatic Neoplasms

NCT05133440 2026-01-21

A Study of Stereotactic Body Radiation Therapy and Radium (Ra-223) Dichloride in Prostate Cancer That Has Spread to the Bones

Phase 2 Active not recruiting

12 enrolled

Genitourinary

Prostatic Neoplasms

NCT05924672 2026-01-14

Efficacy of Ra-223 in PSMA PET Optimally Selected Patients

Phase 2 Active not recruiting

2 enrolled

Genitourinary

Prostatic Neoplasms

NCT03361735 2025-05-02

Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer

Phase 2 Active not recruiting

25 enrolled

Genitourinary

Prostate Adenocarcinoma

NCT03304418 2025-04-30

RROPE

Phase 2 Completed

20 enrolled 14 charts

Genitourinary

Prostate Cancer Metastatic to Bone

NCT03002220 2024-12-11

EXCAAPE

Phase 2 Completed

52 enrolled 15 charts

Genitourinary

Prostatic Neoplasms

NCT02903160 2024-02-07

Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)

Phase 2 Completed

40 enrolled 18 charts

Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT00337155 2023-11-02

BAY88-8223, Dose Finding Study in Patients With HRPC

Phase 2 Completed

122 enrolled

Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT00667199 2023-04-19

BAY88-8223, Does Response Study in HRPC Patients

Phase 2 Completed

100 enrolled

Genitourinary

Hormone Refractory Prostate Cancer

NCT02346526 2022-09-29

A Biomarker Study of Standard-of-care Radium-223 Chloride for Metastatic Castration-resistant Prostate Cancer

Phase 2 Completed

22 enrolled 14 charts

Genitourinary

Prostatic Neoplasms

NCT02582749 2022-07-11

Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases

Phase 2 Terminated

16 enrolled 6 charts

Genitourinary

Prostatic Neoplasms

NCT03062254 2021-09-21

Metabolic Change in Prostate Cancer Bone Metastases on 68Ga-HBED-CC-PSMA PET/CT Following Radium-223 Therapy

Phase 2 Completed

14 enrolled

Genitourinary

Prostatic Neoplasms

NCT02199197 2020-10-30

Radium Ra 223 With Enzalutamide Compared to Enzalutamide Alone in Men With Metastatic Castration Refractory Prostate Cancer

Phase 2 Completed

49 enrolled 18 charts

Genitourinary

Prostatic Neoplasms

NCT02034552 2019-07-23

A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC)

Phase 2 Completed

68 enrolled 17 charts

Genitourinary

Prostatic Neoplasms

NCT02023697 2019-07-12

Standard Dose Versus High Dose and Versus Extended Standard Dose Radium-223 Dichloride in Castration-resistant Prostate Cancer Metastatic to the Bone

Phase 2 Completed

391 enrolled 53 charts

Genitourinary

Prostatic Neoplasms

NCT02507570 2019-03-19

Open Label Phase Two Study of Enzalutamide With Concurrent Administration of Radium Ra 223 Dichloride in Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Symptomatic Bone Metastasis

Phase 2 Completed

40 enrolled

Genitourinary

Prostate Carcinoma Metastatic to the Bone

NCT01929655 2018-04-24

Japanese BAY88-8223 Monotherapy Phase II Study

Phase 2 Completed

49 enrolled

Genitourinary

Prostatic Neoplasms

NCT02097303 2018-02-01

eRADicAte

Phase 2 Completed

36 enrolled 13 charts

Genitourinary

Prostatic Neoplasms

NCT02656563 2016-10-14

RAND

Phase 2 Withdrawn

Genitourinary

Prostatic Neoplasms

NCT02484339 2016-04-27

α-RT

Phase 2 Unknown

274 enrolled

Genitourinary

Prostatic Neoplasms

NCT00459654 2014-06-25

A Placebo-controlled Phase II Study of Bone-targeted Radium-223 in Symptomatic Hormone-refractory Prostate Cancer

Phase 2 Completed

64 enrolled

Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms